Mettez-vous hors ligne avec l'application Player FM !
The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Manage episode 463381941 series 2739469
We love to hear from our listeners. Send us a message.
Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen Pharmaceuticals and its lead candidate, Sabirnetug, fit on the landscape. We also cover the critical and growing role of biomarkers in matching Alzheimer's therapies to specific patients, and assess the growing demand for CNS therapeutics.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Chapitres
1. The Business Of CNS with Acumen's Jim Doherty, Ph.D. (00:00:00)
2. Neuroscience and Alzheimer's Therapeutics (00:00:04)
3. Advancements in Alzheimer's Therapeutics (00:14:09)
4. Subcutaneous Formulation for Alzheimer's Therapy (00:28:03)
5. Creating a Strategic Path for Success (00:37:11)
242 episodes
Manage episode 463381941 series 2739469
We love to hear from our listeners. Send us a message.
Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen Pharmaceuticals and its lead candidate, Sabirnetug, fit on the landscape. We also cover the critical and growing role of biomarkers in matching Alzheimer's therapies to specific patients, and assess the growing demand for CNS therapeutics.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Chapitres
1. The Business Of CNS with Acumen's Jim Doherty, Ph.D. (00:00:00)
2. Neuroscience and Alzheimer's Therapeutics (00:00:04)
3. Advancements in Alzheimer's Therapeutics (00:14:09)
4. Subcutaneous Formulation for Alzheimer's Therapy (00:28:03)
5. Creating a Strategic Path for Success (00:37:11)
242 episodes
Tous les épisodes
×Bienvenue sur Lecteur FM!
Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.